DCM
SAGE

DAFNA Capital Management’s Sage Therapeutics SAGE Stock Holding History

DAFNA Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-108,200
Closed -$860K – 80
2025
Q1 		$860K Hold
108,200
– – 0.24% 62
2024
Q4 		$588K Hold
108,200
– – 0.15% 70
2024
Q3 		$781K Sell
108,200
-8,000
-7% -$73.2K 0.18% 67
2024
Q2 		$1.26M Buy
+116,200
New +$1.49M 0.3% 58
2024
Q1 		– Sell
-245,000
Closed -$5.31M – 80
2023
Q4 		$5.31M Buy
+245,000
New +$4.86M 1.27% 24
2023
Q3 		– Sell
-180,306
Closed -$8.48M – 78
2023
Q2 		$8.48M Hold
180,306
– – 2.32% 16
2023
Q1 		$7.57M Hold
180,306
– – 2.27% 13
2022
Q4 		$6.88M Hold
180,306
– – 1.94% 15
2022
Q3 		$7.06M Hold
180,306
– – 1.9% 18
2022
Q2 		$5.82M Hold
180,306
– – 1.59% 18
2022
Q1 		$5.97M Hold
180,306
– – 1.56% 18
2021
Q4 		$7.67M Hold
180,306
– – 1.93% 13
2021
Q3 		$7.99M Buy
180,306
+10,000
+6% +$459K 2.12% 12
2021
Q2 		$9.68M Sell
170,306
-11,000
-6% -$778K 2.02% 8
2021
Q1 		$13.6M Hold
181,306
– – 3.22% 5
2020
Q4 		$15.7M Buy
181,306
+23,000
+15% +$1.7M 4.67% 4
2020
Q3 		$9.68M Sell
158,306
-7,000
-4% -$355K 3.15% 6
2020
Q2 		$6.87M Hold
165,306
– – 1.98% 14
2020
Q1 		$4.75M Buy
165,306
+40,500
+32% +$2.35M 1.98% 14
2019
Q4 		$9.01M Hold
124,806
– – 3.09% 8
2019
Q3 		$17.5M Buy
124,806
+1,000
+0.8% +$167K 6.58% 2
2019
Q2 		$22.7M Hold
123,806
– – 8.52% 2
2019
Q1 		$19.7M Buy
123,806
+19,500
+19% +$2.82M 8.49% 2
2018
Q4 		$9.99M Buy
104,306
+5,000
+5% +$572K 4.97% 3
2018
Q3 		$14M Buy
99,306
+3,306
+3% +$510K 5.76% 3
2018
Q2 		$15M Buy
96,000
+2,000
+2% +$314K 7.04% 2
2018
Q1 		$15.1M Buy
94,000
+65,200
+226% +$11.1M 7.37% 2
2017
Q4 		$4.74M Buy
+28,800
New +$2.79M 2.55% 13

Other funds holding SAGE

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

DAFNA Capital Management's SAGE Position: Q2 2025 in Review

DAFNA Capital Management sold out of Sage Therapeutics (SAGE) in Q2 2025, closing a stake of 108,200 shares — an estimated $860K sold.

DAFNA Capital Management first reported a position in SAGE in Q4 2017 and held it in 28 quarters. The position peaked at $22.7M in Q2 2019. 192 funds tracked by Wall St. Rank hold SAGE as of Q2 2025.

  • DAFNA Capital Management reported no remaining Sage Therapeutics position as of Q2 2025 after selling out during the quarter.
  • DAFNA Capital Management sold 108,200 Sage Therapeutics shares in Q2 2025, an estimated $860K.
  • DAFNA Capital Management first reported a position in Sage Therapeutics in Q4 2017 and held it in 28 quarters.
  • DAFNA Capital Management's Sage Therapeutics position peaked at $22.7M in Q2 2019.
  • 192 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2025.

Based on DAFNA Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.